ClinicalTrials.gg
Active, not recruitingNCT04878094Updated Aug 27, 2026

A Study of Intra-operative Imaging in Women With Ovarian Cancer

A Phase 3 interventional study of Intravenous Indocyanine Green/ICG injection and PINPOINT endoscopic fluorescence imaging system in Ovarian Cancer and Ovarian Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 9 sites in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 3, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
155
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center — 5 open to participants now, 16 under way, 2 of them phase 3. Ovarian Neoplasms · Memorial Sloan Kettering Cancer Center.

Enrollment
8th of 49
155 · median 36
Started
2021
with 2 others
Phase 3
2 of 80
none open now
Primary completion
2027-05
later than 6 of 15 live
Registered
74th of 80
by date

Among the 80 studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 8th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2021, is one of 2 in phase 3, reaches primary completion later than 6 of the 15 other live ones, and was the 74th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 80 studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether using the PINPOINT imaging system intra-operatively can reduce the risk of anastomotic leaks and other complications after surgery for ovarian cancer, compared with standard intra-operative assessments alone. The PINPOINT endoscopic fluorescence imaging system uses a special camera and a fluorescent (glowing) dye that can evaluate the blood flow of the bowel in real-time. If there is an area that appears concerning, the surgeon can correct the problem during the procedure.

03

Conditions studied

  • Ovarian Cancer
  • Ovarian Carcinoma

Browse trials for

Keywords

  • Ovarian cancer
  • PINPOINT
  • rectosigmoid resection
  • anastomosis
  • 21-202
  • Memorial Sloan Kettering Cancer Center
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Participant Inclusion Criteria

Part 1 (pre-operative):

  • 18 years or older
  • Diagnosed with primary or recurrent ovarian, fallopian tube, or primary peritoneal cancer
  • Scheduled to undergo debulking or cytoreductive surgery
  • Suspected need for a low anterior rectosigmoid resection at the time of a debulking procedure
  • Enrolled and consented before the operation

Part 2 (intra-operative):

  • Completed rectosigmoid resection
  • Surgeon plans to perform colorectal anastomosis

Participant Exclusion Criteria

Part 1 (pre-operative):

  • Documented history of allergic reaction to ICG
  • Not approached for study enrollment before undergoing an unexpected low anterior rectosigmoid resection

Part 2 (intra-operative):

  • Did not undergo rectosigmoid resection intraoperatively
  • Surgical procedure with rectosigmoid resection for any other type of gynecologic
  • Patient requires permanent colostomy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Active comparator
    Arm A

    Randomized to standard technique and assessment of anastomosis without the use of NIR angiography

    Diagnostic Test: Endoscopy

  • Experimental
    Arm B

    Randomized to additional assessment of proximal colonic stump and anastomotic perfusion using NIR angiography

    Diagnostic Test: Intravenous Indocyanine Green/ICG injection · Diagnostic Test: PINPOINT endoscopic fluorescence imaging system · Diagnostic Test: Endoscopy

Interventions

  • Diagnostic testIntravenous Indocyanine Green/ICG injection

    Intravenous Indocyanine Green/ICG injection will be administered for visualization

  • Diagnostic testPINPOINT endoscopic fluorescence imaging system

    After resection the surgeon will use the PINPOINT imaging system to assess perfusion of the colonic stump. The intervention will again be used following establishment of the anastomosis, however this time via a proctoscope to visualize the proximal and distal ends of the rectosigmoid anastomosis.

  • Diagnostic testEndoscopy

    Standard technique and assessment of anastomosis without the use of NIR angiography

06

What researchers measure

Primary outcomes

  1. Reduction of the risk of 30-day postoperative anastomotic leak at the site of rectosigmoid resection, compared with standard intraoperative assessment alone

    To determine whether the use of NIR angiography assessment of perfusion at the time of rectosigmoid resection in a cohort of patients undergoing surgery for ovarian cancer reduces the risk of 30-day postoperative anastomotic leak at the site of rectosigmoid resection, compared with standard intraoperative assessment alone.

    Time frame: 45 days post procedure

07

Study locations

9 sites
08

References and documents

Publications

  • Leitao MM Jr, Iasonos A, Tomberlin M, Moukarzel LA, Price H, Bennetti G, Ramesh B, Chi DS, Long Roche K, Sonoda Y, Al-Niami A, Mueller JJ, Gardner GJ, Broach V, Jewell EL, Kim S, Feinberg J, Abu-Rustum NR, Zivanovic O. ARIA II: a randomized controlled trial of near-infrared Angiography during RectosIgmoid resection and Anastomosis in women with ovarian cancer. Int J Gynecol Cancer. 2024 Jul 1;34(7):1098-1101. doi: 10.1136/ijgc-2024-005395. PubMed 38514101 ↗

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for May 2027, 72 months after the start.

Of 52 non-industry phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 115. This study's planned 72 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2021
First posted
May 7, 2021
StartActual
May 3, 2021
Primary completionEst.
May 3, 2027
CompletionEst.
May 3, 2027
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04878094
Responsible party
Sponsor
First posted
May 7, 2021
Start date
May 3, 2021
Primary completion
May 3, 2027 (estimated)
Completion
May 3, 2027 (estimated)
Last update
Aug 27, 2026

Study contacts

Mario Leitao, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion